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Background: The coronavirus disease 2019 (COVID-19) pandemic has impacted
people with substance use disorders (SUDs) worldwide, and healthcare systems have
reorganized their services in response to the pandemic.
Methods: One week after the announcement of the COVID-19 as a pandemic, in a
global survey, 177 addiction medicine professionals described COVID-19-related health
responses in their own 77 countries in terms of SUD treatment and harm reduction
services. The health responses were categorized around (1) managerial measures and
systems, (2) logistics, (3) service providers, and (4) vulnerable groups.
Results: Respondents from over 88% of countries reported that core medical and
psychiatric care for SUDs had continued; however, only 56% of countries reported
having had any business continuity plan, and 37.5% of countries reported shortages of
methadone or buprenorphine supplies. Participants of 41% of countries reported partial
discontinuation of harm-reduction services such as needle and syringe programs and
condom distribution. Fifty-seven percent of overdose prevention interventions and 81%
of outreach services were also negatively impacted.
Conclusions: Participants reported that SUD treatment and harm-reduction services
had been significantly impacted globally early during the COVID-19 pandemic. Based
on our findings, we highlight several issues and complications resulting from the
pandemic concerning people with SUDs that should be tackled more efficiently during
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the future waves or similar pandemics. The issues and potential strategies comprise the
following: (1) helping policymakers to generate business continuity plans, (2) maintaining
the use of evidence-based interventions for people with SUDs, (3) being prepared
for adequate medication supplies, (4) integrating harm reduction programs with other
treatment modalities, and (5) having specific considerations for vulnerable groups such
as immigrants and refugees.
Keywords: COVID-19 pandemic, substance use disorder, public health, drug policy, opioid agonist treatment,
addiction services, harm reduction
INTRODUCTION
Coronavirus disease 2019 (COVID-19) was announced as a
pandemic by the World Health Organization (WHO) on March
11, 2020 (1). COVID-19 quickly became a global concern given
the rapid transmission of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) (the infectious agent), lack of a
vaccine or evidence-based treatments, person-to-person airborne
spread of SARS-CoV-2, and high mortality of COVID-19 in
specific populations, especially marginalized groups and/or those
with preexisting conditions (2). Lack of capacity to anticipate,
cope with, resist, and recover from COVID-19-related health
consequences are related to individual vulnerability (3). To
manage the current situation successfully, vulnerable groups
should be recognized and helped with special considerations by
relevant health systems (4).
According to the World Drug Report 2020, among ∼269
million people with past-year drug use, over 35 million people
experienced substance use disorders (SUDs) (5). People with
SUDs (PWSUDs) may be particularly vulnerable to COVID-
19 and its complications for multiple reasons (6). PWSUDs
are at a higher risk of psychiatric problems such as mixed
affective states (7); vice versa, polysubstance use and alcohol
use disorder are common among patients with bipolar disorders
(8). Moreover, PWSUDs experience underlying diseases that
constitute risk factors for COVID-19 infection or can be
exacerbated by it; for instance, long-term use of substances
may cause cardiovascular problems (9) and chronic obstructive
pulmonary disease (10). Such comorbidities may exacerbate
superimposed COVID-19 symptoms and lead to highermortality
rates (11). Poor immune system functioning is also prevalent in
PWSUDs because of chronic alcohol and drug use and blood-
borne or sexually transmitted illnesses (12), poor nutritional
status (13), and socioeconomic factors (14). Among PWSUDs,
people who inject drugs (PWIDs) are at exceptionally high risk
of COVID-19, as well as overdoses, unsafe injections, and risky
sex (15).
Psychological conditions (e.g., phobia, anxiety, and panic
attacks) during natural disasters and pandemics, which may
be precipitated, perpetuated, or exacerbated through social
isolation and quarantine, may lead at-risk people to start
and/or relapse into drug taking (11, 16). Psychiatric comorbidity
has a negative impact on recovery from COVID-19 and
may increase the risk of non-fatal and fatal overdoses and
suicides (16). In the general population, COVID-19 and
related concerns such as potential mortality may act as
internal stressors (17) and promote cognitive impairments
(18) in domains such as decision making (19), problem
solving (20), and attention (21) and thus may increase the
incidence and prevalence of psychiatric disorders including
PWSUDs (22).
Stigma may undermine social cohesion, contributing to
situations in which the virus is more, not less, likely to spread.
Such spread may result in more severe health problems and
difficulties controlling a disease outbreak (23). There is an
elevated likelihood for PWSUDs to be homeless and live in
crowded shelters and neighborhoods (24). Synergistically, poor
economic status linked to limited access to health care (25)
may exacerbate risks for PWSUDs and PWIDs (15). Drug
supply chains may be disrupted, and changes in licit and illicit
markets may be accompanied by reductions in quality and
safety (5, 26).
Furthermore, patients’ accessibility to treatment services
could be restricted due to lockdown policies (27). Patients
receiving opioid agonist treatment (OAT) may not be able
to access daily doses of medications (11); spatial distancing
may make home detoxification difficult; and closing of non-
essential services and utilizing staff and other resources to
manage acute COVID-19 cases could result in sudden and
uncoordinated closures of services for PWSUDs (26). Individuals
who use multiple substances may be particularly impacted (28).
Adaptive capacities of systems to epidemic situations that need
coordinated responses may relate directly to vulnerabilities of
the same systems (29). Accessibility to and equal distribution
of wealth (financial and other resources, reliable and correct
information and communication channels, appropriate and
proportionate working technologies) compounded by reductions
in social and relationship capital may impact social resilience to
coping with pandemics (30).
To understand better complexities that are challenging
addiction treatment and harm reduction services globally,
the International Society of Addiction Medicine (ISAM)
has been conducting a global longitudinal survey aiming
to evaluate rapidly and over time how different countries
are maintaining and/or reorganizing their substance use
treatment and harm reduction services during the COVID-
19 pandemic. This paper will report how different countries
have adapted their health system response to emerging needs
in the first month after the WHO’s official announcement of
the pandemic.
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METHODS
Description of the methodology used for this survey has been
published as a study protocol (31). Potential respondents were
contacted onApril 4, 2020 asking about the COVID-19 pandemic
impact on PWSUDs in their own countries. Data collection was
concluded on May 8, 2020.
Questionnaire
The questionnaire consisted of 92 questions in two main
areas: (1) situation assessment during the pandemic and (2)
health responses to the pandemic. This paper will focus on
health responses during the COVID-19 pandemic period (31).
Results on the situation assessment are reported in another
publication (32).
Questions around health responses to the pandemic were
grouped into three categories:
(1) systems available to respond to acute emerging needs
due to the COVID-19 pandemic within substance
use services;
(2) availability of protocol and/or guidelines around COVID-19
and PWSUDs, and
(3) reduction in face-to-face contacts because of
lockdown policies.
To assess respondents’ overall views, they were asked to score
the “overall situation at a glance” rating scale questions (RSQ)
(between 1 and 10 with 1 for the worst situation and 10 for
the best situation) based on their opinion regarding the overall
quality of the situation of their country for each of the above
three sections.
Categorization of Countries Based on
Their Income
The 2019 statistical annex of World Economic Situation and
Prospects (WESP) (33) was used to categorize responding
countries. Very low- and low-income categories were
merged into one, retaining middle- and upper-income
countries designations. In figures, countries’ names are sorted
alphabetically in each group of high-, middle- and low-income
categories. The number of respondents (for countries with
more than one respondent) is indicated in front of their names,
and numbers in each column represent valid responses from
each country.
Statistical Analysis
Statistical analyses were performed using SPSS version 22 (IBM
Corp., Armonk, NY, USA) and RStudio (version 1.2.1335).
Descriptive data are presented as means and percentages for each
country’s response mean (percentage), as well as an average to the
global responses.
Ethics Approval
The survey protocols and all materials, including the survey
questionnaires, received approval from the University of Social
Welfare and Rehabilitation Sciences, an ethics committee in
Tehran, Iran (Code: IR.USWR.REC.1399.061).
RESULTS
Participants
A total of 177 respondents from 77 countries participated.
Figure 1 shows the distribution of the countries and the
number of participants from each. Among 177 respondents,
FIGURE 1 | Global distribution of the respondents to the survey. Number of participants from each country is demonstrated as a color spectrum from light to
dark purple.
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95 (53.7%) were from high-income, 34 (19.2%) from middle-
income, and 48 (27.1%) from low-income countries (“World
Economic Situation and Prospects 2019,” 2019). Table 1 shows




Among respondents from high-income countries (N = 95),
69% answered that business continuity/contingency plans had
been implemented in their countries to make sure that services
continued to operate for PWSUDs during the COVID-19
pandemic compared to 40.7% in the middle-income (N =
34) and 53.8% (N = 48) in low-income countries. Overall,
respondents from 56% of participating countries reported that
business contingency plans had been arranged to help ensure the
continuity of services during the pandemic (Figure 2).
Availability and Accessibility of Treatment
and Harm Reduction Services
Among respondents from high-income countries (N = 95),
57% answered that treatment and harm reduction services
for PWSUDs had been available and accessible in their
countries during the pandemic onset compared to 51.6% in
the middle-income (N = 34) and 63% in low-income (N =
48) countries. Overall, respondents from 59% of participating
countries reported that treatment and harm reduction services
for PWSUDs had been available and accessible during the initial
period of the COVID-19 pandemic (Figure 2).
Respondents from over 81% of participating countries (N
= 77) reported having experienced limitations in the usage of
any outreach services due to lockdown policies for homeless
PWSUDs. Furthermore, respondents from 57% of participating
countries reported having experienced limitations in their harm
reduction overdose services during the initial period of the
pandemic. Problems with the distribution of take-home naloxone
were reported by respondents from 57% of participating
countries. Respondents from 54.8% of the participating countries
reported shortages in needle and syringe programs (NSPs) and/or
with respect to condom distribution.
Medical and Psychiatric Care During the
Initial Period of the Pandemic
Among respondents from high-income countries (N = 95),
90% answered that medical and psychiatric care for PWSUDs
had been available during the initial stages of the pandemic
compared to 77.4% in middle-income (N = 34) and 79.5% in
low-income (N = 48) countries. Overall, respondents in 88%
of participating countries reported that necessary medical and
psychiatric care for PWSUDs had continued in their countries
during this period (Figure 2). However, respondents in 37.5% of
participating countries reported having experienced shortages of
opioid medications (methadone or Buprenorphine) (Figure 3).
Only 44.3% of respondents from high-income (N = 95),
32.2% from middle-income (N = 34), and 40.1% from low-
income (N = 48) countries reported that COVID-19 screening
TABLE 1 | Survey respondents’ demographic, educational, and professional












Age (year) 46.5 (10.8) 49.9 (10.1) 44.9 (8.2) 41.0 (11.2)
Gender
Female 62 (35%) 39 (41.1%) 9 (26.5%) 14 (29.2%)
Male 111 (62.7%) 55 (57.9%) 23 (67.6%) 33 (68.8%)
Others 4 (2.3%) 1 (1.1%) 2 (5.8%) 1 (2.1%)
Degree
BSc. 6 (3.4%) 4 (4.2%) 1 (2.9%) 1 (2.1%)
MSc 13 (7.3%) 2 (2.1%) 3 (8.8%) 8 (16.7%)
MD 72 (40.7%) 35 (36.8%) 11 (32.4%) 26 (54.2%)
PhD 31 (17.5%) 19 (20%) 9 (26.5%) 3 (6.2%)
MD, MSc 13 (7.3%) 9 (9.5%) 2 (5.9%) 2 (4.2%)
MD, PhD 32 (18.1%) 22 (23.2%) 5 (14.7%) 5 (10.4%)
Others 10 (5.6%) 4 (4.2%) 3 (8.8%) 3 (6.2%)
Discipline
Addiction Medicine 19 (10.7%) 17 (17.9%) 0 (0%) 2 (4.2%)
Drug/Health Policy 8 (4.5%) 4 (4.2%) 1 (2.9%) 3 (6.2%)
General Medicine 17 (9.6%) 10 (10.5%) 6 (17.6%) 1 (2.1%)
Other Medical
Specialties
3 (1.7%) 1 (1.1%) 1 (2.9%) 1 (2.1%)
Pharmacology 2 (1.1%) 2 (2.1%) 0 (0%) 0 (0%)
Psychiatry 95 (53.7%) 51 (53.7%) 13 (38.2%) 31 (64.6%)
Psychology/
Counseling
20 (11.3%) 8 (8.4%) 9 (26.5%) 3 (6.2%)
Social Work 5 (2.8%) 0 (0%) 3 (8.8%) 2 (4.2%)
Others 8 (4.5%) 2 (2.1%) 1 (2.9%) 5 (10.4%)
Variables are reported as mean (standard deviation) or count (percent %).
NA, not applicable; BSc, Bachelor of Science; MD, Doctor of Medicine; MSc, Master of
Science; PhD, Doctor of Philosophy; Sig, significance; SD, standard deviation.
and/or diagnosis test kits based on local/national guidelines for
PWSUDhad been available in their country. Overall, respondents
from only 48% of the participating countries reported that
there had been enough personal protective equipment (PPE)
available for PWSUDs during the initial stage of the pandemic.
Respondents from 77.7% of participating countries reported
SUD health workers’ safety as a concern for employers in
the outpatient treatment centers, 66.4% had received training
regarding their safety, and 72.9% reported that they had had
access to enough PPE (Figure 3).
The distribution of other responses on the effect of COVID-
19 on substance use treatment and/or harm reduction services
to vulnerable groups such as children, women, pregnant women,
and immigrants or refugees can be seen in Table 2 and Figure 4.
Table 2 shows the existence of services for children, women,
pregnant women, and refugees or immigrants among the
countries based on their income group.
Overall, 22.8% of all respondents replied that service for
children continued as usual compared to 77.2% that replied
service for children continued but with limitations. According to
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FIGURE 2 | Availability and accessibility of treatment and harm reduction services. Data relating to arranging business continuity plans (Business C Plan), limitations
that mobile services faced during the pandemic (mobile services limitation), limitations that harm reduction services faced during the pandemic (HR services limitation),
(Continued)
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FIGURE 2 | and continuity of other medical and psychiatric necessary care (Med Psyc Care Cont.) are depicted. The Figure shows responses from respondents from
77 countries categorized into low-, middle-, and high-income countries. The light green bars and the numbers associated with each country show the survey
respondents who reported having experienced limitations regarding the question in their country (Yes), and the gray bars show the survey respondents who reported
having experienced no limitations regarding the question in their country (No). The dark green bars show the overall responses in each category (low, middle, and high
income) as well as overall responses.
TABLE 2 | Services for children, women, pregnant women, and refugees or













Children 80.8 (130) 79.4 (63) 92.3 (26) 75.6 (41)
Women 95.4 (153) 96.3 (81) 96.6 (30) 92.8 (42)
Pregnant Women 88 (149) 88.4 (78) 89.3 (28) 86) 43)
Immigrants/Refugees 70.1 (124) 68.2 (63) 82.6 (28) 65.8 (34)
b. Continued as Usual
Children 22.8 (30) 18 (12) 16.6 (5) 35.5 (15)
Women 21 (33) 16.6 (14) 20.7 (6) 28.2 (12)
Pregnant Women 28.2 (42) 23.2 (18) 28 (8) 37.8 (16)
Immigrants/Refugees 18.4 (23) 11.6 (8) 21 (6) 28 (10)
c. Continued with Limitations
Children 77.2 (100) 82 (51) 83.3 (21) 64.5 (26)
Women 79 (120) 77.2 (67) 83.4 (24) 79.3 (30)
Pregnant Women 71.8 (107) 76.8 (60) 72 (20) 62.2 (27)
Immigrants/Refugees 81.6 (101) 88.4 (55) 79 (22) 72 (24)
Availability of the services is reported in Part a. Continuity of the service as usual or with
limitations among countries that have the service available is reported in Parts b and c.
Percent has been calculated based on Yes response in the respondents in each group
of income.
the responses, in all three groups of income countries, treatment
and/or harm reduction services for pregnant women were a
group with minimum impact from COVID-19. Refugees and
the immigrant population was the group that their services
impacted more than other groups due to COVID-19. Only 18.4%
replied that service for refugees and/or immigrants population
continued as usual, and 81.6% replied that this service continued
but with limitations.
Health Policies for COVID-19 Among
PWSUDs
Overall, respondents from 48% of the participating countries
reported the presence of local and/or national guidelines tailored
to be used during the initial stage of the pandemic (60.2% in
high-income, 57.1% in middle-income, and 29% in low-income
countries). Among respondents from high-income countries,
65.7% answered that there had been a protocol available for
COVID-19 screening in various treatment sectors for PWSUDs
or harm reduction facilities compared to 60% in middle-income
and 82.3% in low-income countries.
Over 76% of respondents from high-income, 63.3% from
middle-income, and 63% from low-income countries reported
that there had been guidelines available that helped service
providers in the management and/or referral of PWSUDs with
symptoms of COVID-19.
Most respondents replied that there had been plans to restrict
personal contacts and decrease patients’ commutes for treatment
in their countries (86, 90, and 86.6% in high-, middle- and low-
income countries, respectively, and 85% overall) due to their
national and regional lockdown policies.
As a result, respondents from 80% of the participating
countries reported that clinicians had been prescribing longer-
period prescriptions (e.g., 28 days rather than weekly) to
PWSUDs during the onset of the pandemic (Figure 5).
Additionally, around 69% of participating countries reported
that clinicians within OAT programs had provided more take-
home doses of methadone and/or Buprenorphine during the
onset of the pandemic. Regionally, 61.6% of respondents from
high-income, 50% from middle-income, and 27.7% from low-
income countries reported that this approach had been used in
their countries (Figure 5).
Respondents from high-income countries most frequently
reported having had the availability of long-acting injectable
Buprenorphine (34.9%; n = 63). Overall, respondents from 22%
of participating countries reported that long-acting injectable
Buprenorphine had been available as a therapeutic option.
Figure 6 shows the average score of each question based on
income categorization. The maximum contrast between high-
and low-income countries was seen in the availability and
access to treatment and harm reduction services. Maximum
and minimum differences between high- and middle-income
countries were observed in flexibility in service provision and
countries’ reactions to the COVID-19 pandemic, respectively.
An average for all rating scale questions in different domains
has been calculated, and Figure 7 shows the results in a global
map format.
DISCUSSION
The emergence of COVID-19 in early 2020 raised considerable
challenges for substance use treatment and harm reduction
programs worldwide, as reflected in this global survey. The
need for effective spatial distancing and isolation to protect
patients, the treatment workforce, and people in contact with
patients and health workers have placed increased demands
on treatment services provision, with potential imbalances in
impact on particularly vulnerable patient populations (28). Here,
in this global survey, we have explored different challenges
and health responses in 77 countries. Our findings showed
that respondents from 56% of participating countries reported
business contingency plans had been arranged to help ensure that
services would continue to operate during the pandemic, which
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FIGURE 3 | Medical services for people with substance use disorders during the pandemic. The responses of respondents from 77 countries are shown, categorized
into low-, middle-, and high-income countries to the questions related to the shortages in opioid medication (opioid short.), disruption in needle and syringe and/or
condom distribution services (NSP Short.), availability or shortages in take-home naloxone services (TH Naloxone short.), availability of COVID-19 screening kits and
equipment for people with substance use disorders (PWSUDs) in their countries (COVID-19 screening), and personal protective equipment provision to PWSUDs (PPE
for SUD patients).
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FIGURE 4 | Effects of COVID-19 on substance use treatment and/or harm reduction services for vulnerable groups. Services for children, pregnant women, refugees,
and women, in high-, middle-, and low-income countries are depicted. The red, yellow, and green bars depict the responses indicating lack of availability of services
during the COVID-19 pandemic, the existence of limited services, and usual service provision, respectively.
is compatible with responses to another question indicating
that 41% of respondents believed there had not been sufficient
availability and accessibility of treatment and harm reduction
services during the onset of the pandemic in their countries at
the time of survey completion.
As a preventative measure to reduce COVID-19 spread, all
international and national published guidelines advised limited
but effective ways regarding how to initiate treatment, support
stabilization, and maintenance and continue to provide harm
reduction measures to treatment-seeking and other populations
with substance use problems (4, 34). These recommendations
often included extending flexibility in OAT services with reduced
supervision of doses and increased home delivery (35). Another
step taken to adjust to the present situation included expanding
telemedicine and teletherapy services (5, 28, 34).
The COVID-19 pandemic is synergistically interacting with
a substance use epidemic globally, creating a syndemic [defined
as a synergistic epidemic, the aggregation of two or more
concurrent or sequential epidemics, which exacerbate the
prognosis and burden of disease (36)]. During the COVID-
19 pandemic, marginalized people, including PWSUDs, are at
greater risk of increased morbidity and mortality (37). These
syndemic disadvantaged populations may be more likely to
experience disparate, possibly substandard, service provision
in systems prioritizing resource needs around a pandemic
response (Inverse Response Law and Inverse Care Law) (38).
Such inequities may present at macrolevels around effective
and appropriate policymaking at national, organizational, and
local levels (38) and at microlevels around areas of access
to resources, social services, public health benefits of medical
treatments, pharmacies, healthcare facilities, and provision of
medical equipment (39).
Proactive business continuity plans for PWSUDs are
important for all governments as part of COVID-19
remobilization plans and possible future responses to similar
pandemics to support and avert delays and inequities in
responses. Overall, PWSUDs are at risk for a negative impact
of COVID-19 (6); it is also essential to mention that gender
differences play a substantial role in the vulnerabilities of
PWSUDs (40). Our findings showed that 88% of respondents
reported continuity of other necessary medical and psychiatric
care compared to <60% who reported the existence of business
continuity/contingency plans and enough availability and
accessibility of treatment and harm reduction services for
PWSUDs. These findings suggest that policymakers and
health authorities in each country could have possibly made
more appropriate decisions in order to protect at-risk and
marginalized PWSUDs including those who may be homeless,
have HIV/AIDS, hepatitis, or multiple and complex morbidities.
Such decisions may involve considering how to subtly provide
scheduled and new appointments and prescription medications
in the circumstances of lockdowns.
This study has multiple limitations that have been described
in detail in the study protocol of the survey (31). The responses
obtained were intentionally based around personal opinions of
addiction medicine experts to help understand the “state of
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FIGURE 5 | Health policies for COVID-19 among people with substance use disorders (PWSUDs). Plans to restrict any personal contact, provision of prescriptions of
longer durations, provision of more take-home doses of opioids drugs, and availability of any program for delivering opioid drugs to patients’ homes are depicted. The
(Continued)
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FIGURE 5 | Figure shows responses from 77 countries, which are categorized into low, middle, and high income. The light green bars and the numbers associated
with each country show the survey respondents who reported having experienced limitations regarding the question in their country (Yes), and the gray bars show the
survey respondents who reported having experienced no limitations regarding the question in their country (No). The dark green bars show the overall responses in
each category (low, middle, and high income) as well as overall responses.
FIGURE 6 | Flexibility of health responses for people with substance use
disorders in response to the pandemic in different domains based on the
income levels of the countries. Respondents were asked to rate the overall
flexibility of their health system in nine different domains, from 1 (extremely
poor) to 10 (extremely good).
things in real life” rather than objective epidemiological data,
which would have been considerably delayed. Therefore, ethical
approval has not been taken from each of the countries that
participated in the survey. The limited number of respondents
makes this information non-representative and possibly biased.
In other words, the survey results might be subject to bias
and not demonstrate a true reflection of addiction services
in their countries. Hence, the findings (opinions) have a
high chance of subjective biasing. Sampling bias is another
limitation, and indeed due to sampling methodology, the
participants were not necessarily oriented to all domains of
the questionnaire.
Given the urgency of the COVID-19 pandemic, the paper aims
to alert and inform colleagues around the world and facilitate
collaboration. Due to the time limitations, the questionnaire was
circulated only in English. Therefore, some experts may have
withdrawn from the survey for lingual reasons, and others may
have answered questions less precisely.
CONCLUSIONS
Based on our findings in this global survey, we conclude that
the addiction medicine systems in all countries, regardless of
income level, have been affected to some degree by the COVID-
19 pandemic. Depending on the different domains and the ability
of countries to adapt to existing conditions, these effects may
differ across jurisdictions. Income level may relate importantly to
responses and impact vulnerable groups like PWSUDs. Although
this survey’s findings should be interpreted with caution, the
translation of our study results as recommendations for addiction
medicine services, and policymakers would hopefully support a
more resilient system of care that improves responses to future
COVID-19 waves and other pandemics.
Continuity of services, especially in crises, needs certain
evidence-based and locally tailored protocols and guidelines.
In our study, addiction medicine professionals reported that
most of their countries did not provide early guidelines or
protocols to tailor their services to the pandemic. It is important
to consider that respondents in only one-third of low-income
countries reported the availability of such guidelines compared
to respondents in half of the high-income countries. Another
survey (41) conducted in four high-income regions (New South
Wales, Ireland, Scotland, New York State, and British Columbia)
found that special guidelines in response to the new situation and
assurance of continuity of the services were available very soon
after the start of lockdown, which is consistent with our findings
that high-income countries had a more timely response in this
domain. In the absence of guidelines and protocols, clinicians and
service providers may not effectively balance various competing
ethical and professional issues when they are making clinical
and operational decisions when many things may be happening
that could potentially be conflicting in nature (e.g., maintaining
stability but reducing therapeutic contacts). Guidelines also
allow stakeholders to improvise and identify innovative ways
through evidence-based solutions to decrease the dual burden
of substance use and COVID-19 infection (42). International
organizations such as the WHO and United Nations Office
of Drug Control (UNODC) and other related groups such
as the International Society of Addiction Medicine (ISAM),
International Society of Substance Use Professionals (ISSUP),
and World Federation Against Drugs (WFAD) should provide
adequate support to raise policymakers’ knowledge in the area
of addiction medicine on how to establish business continuity
committees during initial stages of pandemics in order to make
advanced care planning decisions through effective leadership.
Additionally, our results showed that respondents reported
the shortage of opioid medication for maintenance treatment
from about 40% of participating countries. Lack of opioid
medications in patients undergoing maintenance treatment is a
risk factor for a lapse, relapse, and/or overdoses. This situation
Frontiers in Psychiatry | www.frontiersin.org 10 April 2021 | Volume 12 | Article 639393
Radfar et al. COVID-19 and Addiction Treatment Services
FIGURE 7 | The overall quality of health response to COVID-19 pandemic based on the subjective ratings by respondents from different countries. Average scores
were measured based on responses in nine domains depicted in Figure 6. Score 1 represents the worst quality in response, and 10 represents the best situation in
favor of health services. Average scores for each country are shown using a color spectrum from yellow to blue.
may become more severe when transport and other supply
chains are disrupted, compounded with the reduced provision
by pharmacies and other dispensing outlets either due to spatial
distancing, and reduced hours of service and/or closing during
the pandemic.
According to this finding, we recommend that governments
and local authorities be cognizant that an effective response
system is based on a well-informed and supportive environment.
Available and communicated international and national clinical
guidelines are pivotal in future responses to similar pandemics
when supporting PWSUDs.
The World Drug Report 2020 stated that “If Governments
respond the same way to the current economic slump, interventions
such as prevention of drug use and related risk behaviors and drug
treatment services could be hard hit” (43). Substance use accounts
for∼11% of the global health burden (44). Treatment is a critical
strategy for reducing the burden of the disease. A study of World
Mental Health Surveys (45) found that only 7.1% of PWSUDs
had received at least minimally adequate treatment in the past
year (10.3, 4.3, and 1.0%, respectively, in high-, upper-middle,
and low/lower-middle-income countries) (46). Poor access to
treatment, awareness/perceived treatment need, and compliance
(on the part of both provider and client) have been reported to be
the main barriers to substance use treatment (46).
Our results also show that harm reduction services seem
to be among the most affected during the initial stages of
the COVID-19 pandemic. Eighty-one percent of participating
countries reported limitations in usage of any mobile and
other outreach services due to lockdown policies for homeless
PWSUDs, with respondents from 57% of participating countries
reporting limitations in their harm reduction overdose services
during the initial period of the pandemic. This was compounded
with reported problems with the distribution of take-home
naloxone as reported by respondents from 57% of participating
countries. Finally, respondents from 54.8% of participating
countries reported that there had been shortages at needle and
syringe programs and/or of condom distribution. International
organizations with regional and local government structures
should create contingencies around adequate supplies of
medications such as methadone and Buprenorphine. Harm
reduction services, especially outreach services, are among the
most effective strategies for preventing HIV, hepatitis C virus
(HCV), and hepatitis B virus (HCV) transmission among the
most at-risk populations (47).
Pregnant women and immigrants/refugees with SUDs are
particularly among vulnerable groups. According to our survey
responses, pregnant women were perceived as relatively less
impacted during the initial period of the pandemic. This is
reassuring, as discontinuity of treatment services could place not
only a pregnant woman at high risk but also the developing fetus.
However, refugee and immigrant populations were reported as
having had their services impacted more than other groups due
to the pandemic. Only 12.9% of respondents replied that service
for refugees and/or immigrants population continued as usual,
and 57.3% replied that this service continued but with severe
limitations (48).
These findings highlight the fact that harm reduction
initiatives should be seen as an integral part of an evidence-based
treatment program and not as an adjunct to failed treatment
and/or solely as a public health response to reduce blood-borne
diseases. Service providers should be considering identifying
person-centered, continuous care provision in all therapeutic
options available (harm reduction initiatives included), especially
during pandemic situations.
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Lastly, our findings suggest that, in general, in multiple
domains of countries’ reactions to the pandemic (e.g., availability
of and access to treatment and harm reduction, screening and
early interventions, flexibility in service provision and services
for special and high-risk populations), the COVID-19 pandemic
has had a more negative impact that is linked to the income level
of countries. Vulnerable groups such as immigrants and refugees
with SUDs should have access to all possible therapeutic options
available as described in the UN charter in the Human Rights
Convention (“International Convention on the Protection of the
Rights of All Migrant Workers and Members of Their Families”).
Appropriate evidence-based services must be designed and
implemented by health authorities for such vulnerable groups.
Availability of all relevant resources is essential in the delivery of
quality services.
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